Business Context and Reporting Period
Company: Moleculin Biotech, Inc. (MBRX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 11, 2025
Event: Entry into a Material Definitive Agreement (At The Market Offering Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. It details a potential equity financing arrangement.
- Maximum Offering Size: Up to $6,500,000 in aggregate sales price of common stock.
- Placement Fee: 3.0% of the gross sales price of shares sold.
- Legal Reimbursement Cap: Up to $50,000 for counsel fees and disbursements.
- Due Diligence Fee Cap: Up to $5,000 per period.
Material Changes
On July 11, 2025, the Company entered into an At The Market Offering Agreement (ATM Agreement) with Roth Capital Partners, LLC. This agreement authorizes the sale of shares through Roth Capital acting as sales agent and/or principal. The offering is conducted under an effective shelf registration statement (File No. 333-280064) that became effective on July 1, 2024, which covers up to $200,000,000 in securities.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds are intended for working capital and general corporate purposes.
- Sales Method: Sales may be made via "at-the-market" offerings or privately negotiated transactions based on market conditions and the Company's capital needs.
- Termination: The Company may terminate the agreement with two business days' notice. The offering terminates upon the sale of the specified aggregate amount or earlier if terminated by either party.
- Principal Purchases: Roth Capital may purchase shares as principal, but is not obligated to do so unless a separate terms agreement is executed.
Investor Verification Checklist
- Verify the current market price of MBRX common stock to assess potential dilution impact.
- Review the full text of the ATM Agreement (Exhibit 1.1) for specific pricing limitations and suspension rights.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.
- Confirm the Company's current cash position to understand the urgency of the capital raise.